Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Research In Brief

This article was originally published in The Gray Sheet

Executive Summary

HPV screening: Primary human papilloma virus DNA screening with Qiagen/Digene's Hybrid Capture 2 followed by cytology triage is more sensitive in detecting cervical lesions than conventional cytology screening, according to a large-scale Finnish study published in the Dec. 2 issue of the Journal of the National Cancer Institute. In women 35 or older, the method also showed greater specificity and decreased colposcopy referrals and follow-up tests. An accompanying editorial by Eduardo L. Franco, McGill University, notes that as more young women who have received the HPV vaccine reach screening age, "the reduced prevalence of abnormalities may adversely affect the performance of cytology if it is left as the sole screening test.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT028172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel